AstraZeneca’s Calquence Showed Improvement In Small Group Of Hospitalized Covid-19 Patients. ByNathan Vardi, Former Staff. Following the money trail. Jun 05, 2020, 02:24pm EDT. Share. Save.

Calquence, which was approved in the U.S. for chronic lymphocytic leukemia patients in November, was the only product of Acerta, which was acquired by AstraZeneca in a $7 billion deal in 2016.

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65.

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...

Cambridge-based AstraZeneca has revealed plans to launch a 400-patient trial of the leukaemia drug which is thought to work by preventing the virus from scarring the lungs.

RELATED: AstraZeneca's Calquence preps for Imbruvica showdown with phase 3 CLL win. The British drugmaker is keeping the details under wraps for now; they’ll debut at a future medical meeting.

AstraZeneca Calquence CLL Data Sets It Up For Regulatory Submissions In 2019. Jun. 26, 2019 8:20 PM ET AstraZeneca PLC (AZN) Stock ABBV, JNJ, AZN 7 Comments 1 Like. Terry Chrisomalis.

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia By Angus Liu Dec 8, 2024 11:00am AstraZeneca ASH 2024 Calquence chronic lymphocytic leukemia ...

AstraZeneca PLC said Monday that its Calquence drug showed greater safety than an existing drug without compromising efficacy in a phase 3 trial with adults with previously treated, high-risk ...